CURRENT DRUG TARGETS

Scope & Guideline

Showcasing Breakthroughs in Molecular Medicine

Introduction

Delve into the academic richness of CURRENT DRUG TARGETS with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN1389-4501
PublisherBENTHAM SCIENCE PUBL LTD
Support Open AccessNo
CountryUnited Arab Emirates
TypeJournal
Convergefrom 2000 to 2024
AbbreviationCURR DRUG TARGETS / Curr. Drug Targets
Frequency16 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressEXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES

Aims and Scopes

CURRENT DRUG TARGETS focuses on the identification and validation of drug targets, novel therapeutic strategies, and the development of drug delivery systems. The journal emphasizes multidisciplinary approaches that integrate molecular biology, medicinal chemistry, and clinical applications, contributing significantly to the field of drug discovery and development.
  1. Drug Target Identification and Validation:
    The journal publishes research that explores novel drug targets across various diseases, focusing on understanding molecular mechanisms and signaling pathways relevant to therapeutic interventions.
  2. Innovative Drug Delivery Systems:
    A core area includes the development of advanced drug delivery systems, such as nanoparticles and nanocarriers, that enhance the efficacy and safety of therapeutics.
  3. Therapeutic Approaches for Chronic Diseases:
    CURRENT DRUG TARGETS addresses therapeutic strategies for chronic conditions such as cancer, diabetes, and neurodegenerative diseases, highlighting multitarget and combination therapies.
  4. Natural Products and Traditional Medicine:
    The journal includes studies on natural compounds and their potential as therapeutic agents, emphasizing the importance of traditional medicine in contemporary drug discovery.
  5. Machine Learning and Computational Approaches:
    Research utilizing artificial intelligence and computational methods for drug design and target prediction is increasingly featured, reflecting the journal's commitment to modernizing therapeutic development.
CURRENT DRUG TARGETS is witnessing a significant evolution in research themes, with several emerging trends reflecting the current priorities and technological advancements in drug discovery.
  1. Nanotechnology in Drug Delivery:
    A growing number of publications focus on nanotechnology-based delivery systems, showcasing their effectiveness in improving drug solubility, targeted delivery, and therapeutic outcomes.
  2. Multitarget and Combination Therapies:
    There is an increasing interest in developing multitarget compounds and combination therapies to enhance treatment efficacy and overcome drug resistance, particularly in oncology and chronic diseases.
  3. Artificial Intelligence in Drug Design:
    The integration of AI and machine learning in drug design and target identification is trending, as researchers seek to leverage computational tools to accelerate the discovery process.
  4. Natural Products as Therapeutics:
    A resurgence in the exploration of natural products for drug development is evident, with studies highlighting their potential in treating complex diseases and enhancing therapeutic efficacy.
  5. Personalized Medicine and Biomarkers:
    Research focusing on personalized medicine approaches, including biomarker identification for tailored therapies, is gaining traction, reflecting the shift towards individualized treatment strategies.

Declining or Waning

While CURRENT DRUG TARGETS has consistently covered a wide range of topics in drug discovery, certain areas are becoming less prominent in recent publications. This shift reflects evolving research interests and advancements in technology.
  1. Traditional Pharmacology Approaches:
    There is a noticeable decline in the emphasis on traditional pharmacological methods, with a shift towards more innovative and technology-driven approaches such as nanotechnology and computational drug design.
  2. Single-Target Drug Development:
    The focus on developing drugs aimed at single targets is waning, as the field moves towards multitarget strategies that can address the complexity of diseases more effectively.
  3. Basic Research without Clinical Relevance:
    Papers that do not bridge the gap between basic research and clinical applications are becoming less frequent, indicating a push towards translational research that has immediate therapeutic implications.
  4. Conventional Drug Discovery Models:
    Research employing outdated drug discovery models, such as classic animal studies without innovative methodologies, is declining in favor of more sophisticated, predictive models.

Similar Journals

Acta Pharmaceutica Sinica B

Bridging Knowledge and Innovation in Pharmaceutics
Publisher: INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCESISSN: 2211-3835Frequency: 6 issues/year

Acta Pharmaceutica Sinica B is a prestigious open access journal that has been setting the standard in the field of pharmacology, toxicology, and pharmaceutics since its establishment in 2011. Published by the Institute of Materia Medica, Chinese Academy of Medical Sciences, the journal serves as a vital platform for researchers, professionals, and students seeking to disseminate innovative findings in drug development, pharmaceutical sciences, and therapeutic applications. With an impressive impact factor reflecting its high academic quality, Acta Pharmaceutica Sinica B has achieved Q1 status in the category of Pharmacology, Toxicology and Pharmaceutics as of 2023, ranking #1 out of 80 journals in General Pharmacology. This journal not only focuses on the latest advancements in drug research and formulation but also emphasizes interdisciplinary approaches, fostering collaborations that span various scientific domains. The accessible nature of the journal, combined with its rigorous peer-review process, ensures that crucial insights and breakthroughs reach a global audience swiftly and effectively. For those looking to stay at the forefront of pharmaceutical research, Acta Pharmaceutica Sinica B is an indispensable resource.

DRUG DEVELOPMENT RESEARCH

Advancing pharmaceutical innovation through rigorous research.
Publisher: WILEYISSN: 0272-4391Frequency: 8 issues/year

DRUG DEVELOPMENT RESEARCH is a premier interdisciplinary journal published by Wiley, focusing on the latest advancements in drug discovery, pharmacology, and toxicology. With an ISSN of 0272-4391 and an E-ISSN of 1098-2299, this esteemed publication has been a cornerstone in the field since its inception in 1981 and continues to provide cutting-edge research until 2024. Its rigorous peer-review process and strategic placement in Q2 of the Drug Discovery category, as well as ranking #60 out of 157 in Scopus, underscore the journal's relevance and influence, boasting a respectable 62nd percentile ranking. While the journal does not currently offer open access, it remains a vital resource for researchers, professionals, and students seeking to expand their knowledge on the processes of drug development, identifying new therapeutic targets, and assessing the efficacy and safety of novel compounds. Situated in Hoboken, NJ, this journal stands at the forefront of pharmaceutical innovation, making significant contributions to the advancement of medical science.

MINI-REVIEWS IN MEDICINAL CHEMISTRY

Fostering Knowledge Exchange for Future Medical Breakthroughs.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1389-5575Frequency: 20 issues/year

MINI-REVIEWS IN MEDICINAL CHEMISTRY is a distinguished journal published by Bentham Science Publishers, dedicated to the cutting-edge field of medicinal chemistry. With an ISSN of 1389-5575 and an E-ISSN of 1875-5607, this journal serves as an essential platform for researchers and professionals to disseminate concise yet comprehensive reviews that capture the latest advancements and trends in drug discovery, cancer research, pharmacology, and molecular medicine. Operating since 2001, it has consistently maintained a relevant presence in academia with its impressive rank metrics, including a Q2 category in Drug Discovery and Pharmacology in 2023, highlighting its significance in the scientific community. The journal is recognized for its rigorous peer-review process and provides an invaluable resource for students and researchers seeking insights into the rapidly evolving landscape of medicinal chemistry. With a commitment to excellence and innovation, MINI-REVIEWS IN MEDICINAL CHEMISTRY continues to foster knowledge exchange and inspire future breakthroughs in healthcare and therapeutic advancements.

BIOCHEMICAL PHARMACOLOGY

Exploring the synergy between biochemistry and therapeutics.
Publisher: PERGAMON-ELSEVIER SCIENCE LTDISSN: 0006-2952Frequency: 12 issues/year

BIOCHEMICAL PHARMACOLOGY, published by PERGAMON-ELSEVIER SCIENCE LTD, stands as a leading international journal devoted to the advancing field of biochemical pharmacology. Since its inception in 1958, the journal has continuously offered a platform for innovative research, delivering critical insights into the interaction between biochemical processes and pharmaceutical applications, and now converges towards its 2024 edition. With an impressive Q1 ranking in both Biochemistry and Pharmacology categories, it ranks 32nd out of 313 in Pharmacology and Toxicology, and 58th out of 438 in Biochemistry according to Scopus, showcasing its significant impact within the scientific community. Researchers and professionals rely on this journal to keep abreast of essential developments, given its robust peer-review process and a comprehensive selection of articles that span experimental studies, clinical trials, and theoretical analyses. Although not an Open Access journal, it remains pivotal for those seeking to advance their knowledge in the dynamic fields of biochemistry and pharmacology. With its high impact factor and emphasis on quality research, BIOCHEMICAL PHARMACOLOGY continues to be an invaluable resource for students, researchers, and industry professionals striving to make breakthroughs in drug development and therapeutic strategies.

CANCER CHEMOTHERAPY AND PHARMACOLOGY

Exploring breakthroughs in cancer therapy and drug development.
Publisher: SPRINGERISSN: 0344-5704Frequency: 12 issues/year

Cancer Chemotherapy and Pharmacology, published by Springer, is a leading peer-reviewed journal that plays a crucial role in the field of cancer research and drug therapy. With an ISSN of 0344-5704 and an E-ISSN of 1432-0843, this journal has been a cornerstone of oncology and pharmacology research since its inception in 1978, with continued relevance through to 2024. The journal holds a commendable Q2 ranking in categories such as Cancer Research, Oncology, and Pharmacology (medical), while achieving an elite Q1 status in Toxicology, reflecting its high-impact contributions to the scientific community. Researchers and professionals benefit from access to cutting-edge studies, insightful reviews, and innovative methodologies, making it a vital resource for anyone working at the intersection of pharmacology and oncology. Although not an open-access journal, Cancer Chemotherapy and Pharmacology remains highly accessible through institutional subscriptions, ensuring it reaches a broad audience dedicated to advancing cancer treatment and patient care.

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Exploring the Synergy of Pharmacology and Molecular Medicine
Publisher: AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICSISSN: 0022-3565Frequency: 12 issues/year

The JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, published by the American Society for Pharmacology and Experimental Therapeutics, stands as a pivotal platform in the fields of pharmacology and molecular medicine. With an impressive convergence of knowledge from 1945 to 2024, this esteemed journal is recognized for its rigorous peer-reviewed research, contributing significantly to our understanding of drug action and therapeutic interventions. It holds a commendable position in the Q2 quartile in both Molecular Medicine and Pharmacology, emphasizing its relevance and impact within the contemporary scientific landscape, as evidenced by its Scopus ranking that places it amongst the leading journals in its category. Aimed at researchers, professionals, and students, the journal not only fosters a deeper insight into toxicology, pharmacodynamics, and therapeutic strategies but also encourages innovation through its comprehensive access to groundbreaking experimental methodologies. The journal continues to foster discourse and disseminate research that shapes the future of pharmacological science.

Drug Discoveries and Therapeutics

Empowering researchers with cutting-edge insights.
Publisher: INT RESEARCH & COOPERATION ASSOC BIO & SOCIO-SCIENCES ADVANCEMENTISSN: 1881-7831Frequency: 6 issues/year

Drug Discoveries and Therapeutics is a highly regarded journal devoted to the advancement of knowledge in the field of medicine and pharmacology. Published by the International Research & Cooperation Association for Biological & Socio-Sciences Advancement in Tokyo, Japan, this journal serves as a vital resource for researchers, practitioners, and students interested in the latest developments in drug discovery and therapeutic strategies. With a Scopus ranking of #192 out of 826 in the General Medicine category, and positioning itself in the 76th percentile, it demonstrates a significant impact within the scientific community. The journal publishes original research articles, reviews, and innovative studies that address the complexities of drug development, therapeutic efficacy, and clinical applications. Researchers and clinicians can access valuable insights to enhance their practices and inform further studies as it continues to disseminate crucial findings essential for the advancement of medical science.

European Journal of Pharmacology

Advancing drug discovery through innovative research.
Publisher: ELSEVIERISSN: 0014-2999Frequency: 24 issues/year

The European Journal of Pharmacology, a prestigious publication by Elsevier, serves as a vital resource in the field of pharmacology, offering rich insights into drug development and therapeutic applications. Since its inception in 1967, this journal has evolved to encompass groundbreaking research, including pharmacokinetics, toxicology, and innovative pharmacological methodologies, making it an essential platform for researchers and professionals alike. With an impressive impact factor that places it in the Q1 category of pharmacological journals and a Scopus ranking of #49 out of 313, the journal is recognized in the 84th percentile within its category, solidifying its significance in the academic community. Although the journal is not open access, it continues to attract contributions from leading scientists worldwide, ensuring that cutting-edge findings are disseminated effectively. The European Journal of Pharmacology not only highlights advancements in drug discovery and clinical applications but also promotes interdisciplinary collaboration, ultimately contributing to the progress of healthcare globally.

Anti-Cancer Agents in Medicinal Chemistry

Empowering researchers with cutting-edge insights in oncology.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1871-5206Frequency: 10 issues/year

Anti-Cancer Agents in Medicinal Chemistry is a pivotal journal in the realm of cancer research, published by Bentham Science Publishers in the United Arab Emirates. With an ISSN of 1871-5206 and an E-ISSN of 1875-5992, this esteemed journal has been disseminating high-quality research since its inception in 2006, and is set to continue through 2024. The journal is categorized in the third quartile (Q3) across key areas including Cancer Research, Molecular Medicine, and Pharmacology, highlighting its essential role in providing valuable insights to the scientific community. Despite its open-access status being unspecified, researchers benefit from the rigorous peer-review process ensuring the publication of significant advancements. The journal ranks well within Scopus, particularly in the fields of Pharmacology and Cancer Research, which positions it as a notable resource for professionals, students, and researchers aiming to deepen their knowledge in anti-cancer strategies. Through its comprehensive scope, the journal aims to bridge the gap between medicinal chemistry and clinical applications, making it an indispensable tool for those dedicated to advancing cancer therapeutics.

JOURNAL OF PHARMACY AND PHARMACOLOGY

Fostering collaboration in the realm of drug discovery.
Publisher: OXFORD UNIV PRESSISSN: 0022-3573Frequency: 12 issues/year

Journal of Pharmacy and Pharmacology, published by Oxford University Press, is a prestigious academic journal dedicated to the advancement of knowledge in the fields of pharmaceutical sciences and pharmacology. With a strong heritage dating back to 1949, this journal maintains a robust influence, as evidenced by its ranking in the second quartile (Q2) across both Pharmaceutical Science and Pharmacology categories for 2023. The journal is accessible without an open access option, ensuring traditional academic engagement and providing valuable insights for researchers and professionals. It boasts an impressive Scopus ranking, with a percentile positioning of 72nd in Pharmaceutical Science and 67th in Pharmacology. Aimed at fostering innovative research and facilitating the exchange of cutting-edge scientific knowledge, the Journal of Pharmacy and Pharmacology serves as an essential resource for scientists, students, and healthcare professionals committed to enhancing therapeutic outcomes and advancing pharmaceutical innovations.